These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 33109037)

  • 1. A Randomized Study on the Bioequivalence of Desloratadine in Healthy Chinese Subjects and the Association of Different Metabolic Phenotypes With UGT2B10 and CYP2C8 Genotypes.
    Niu S; Li Y; Dong W; Xia L; Shen T; Wang J; Wang Q; Zhang T; Zhang M; Liu G; Guo D; Fang Y
    Curr Drug Metab; 2020; 21(13):1031-1039. PubMed ID: 33109037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Further Characterization of the Metabolism of Desloratadine and Its Cytochrome P450 and UDP-glucuronosyltransferase Inhibition Potential: Identification of Desloratadine as a Relatively Selective UGT2B10 Inhibitor.
    Kazmi F; Yerino P; Barbara JE; Parkinson A
    Drug Metab Dispos; 2015 Sep; 43(9):1294-302. PubMed ID: 26135009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A long-standing mystery solved: the formation of 3-hydroxydesloratadine is catalyzed by CYP2C8 but prior glucuronidation of desloratadine by UDP-glucuronosyltransferase 2B10 is an obligatory requirement.
    Kazmi F; Barbara JE; Yerino P; Parkinson A
    Drug Metab Dispos; 2015 Apr; 43(4):523-33. PubMed ID: 25595597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study.
    Solans A; Izquierdo I; Donado E; Antonijoan R; Peña J; Nadal T; Carbó ML; Merlos M; Barbanoj M
    Clin Ther; 2008 Sep; 30(9):1639-50. PubMed ID: 18840369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioavailability of two oral formulations of loratadine 20 mg with concomitant ketoconazole: an open-label, randomized, two-period crossover comparison in healthy Mexican adult volunteers.
    Piñeyro-López A; Pineyro-Garza E; Torres-Alanís O; Reyes-Araiza R; Gómez Silva M; Wacksman N; Lujàn Rangel R; de Lago A; Trejo D; Gonzàlez-de la Parra M; Namur S
    Clin Ther; 2006 Jan; 28(1):110-5. PubMed ID: 16490584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain histamine H
    Nakamura T; Hiraoka K; Harada R; Matsuzawa T; Ishikawa Y; Funaki Y; Yoshikawa T; Tashiro M; Yanai K; Okamura N
    Pharmacol Res Perspect; 2019 Aug; 7(4):e00499. PubMed ID: 31338198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relative bioavailability of loratadine administered as a chewing gum formulation in healthy volunteers.
    Noehr-Jensen L; Damkier P; Bidstrup TB; Pedersen RS; Nielsen F; Brosen K
    Eur J Clin Pharmacol; 2006 Jun; 62(6):437-45. PubMed ID: 16770647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clopidogrel and Gemfibrozil Strongly Inhibit the CYP2C8-Dependent Formation of 3-Hydroxydesloratadine and Increase Desloratadine Exposure In Humans.
    Itkonen MK; Tornio A; Neuvonen M; Neuvonen PJ; Niemi M; Backman JT
    Drug Metab Dispos; 2019 Apr; 47(4):377-385. PubMed ID: 30630815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Determination of Desloratadine and Its Metabolite 3-OH Desloratadine in Human Plasma by LC-MS/MS].
    Zhang K; Zhang XQ; Lu W; Xie HR; He L; Jiang XH; Wang L
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2015 Sep; 46(5):783-7, 804. PubMed ID: 26619557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple-dose pharmacokinetics and safety of desloratadine in subjects with moderate hepatic impairment.
    Gupta SK; Kantesaria B; Wang Z
    J Clin Pharmacol; 2007 Oct; 47(10):1283-91. PubMed ID: 17906161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioequivalence Evaluation of Three Pediatric Oral Formulations of Bilastine in Healthy Subjects: Results from a Randomized, Open Label, Crossover Study.
    Sádaba B; Azanza JR; García-Bea A; Labeaga L; Campo C; Valiente R
    Eur J Drug Metab Pharmacokinet; 2020 Apr; 45(2):265-272. PubMed ID: 31820304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of Desloratadine Slow-metabolizer Phenotype and Food-dependent Pharmacokinetics of Desloratadine in Healthy Chinese Volunteers.
    Wang T; Zhang K; Li T; He L; Xie H; Jiang X; Wang L
    Clin Drug Investig; 2015 Dec; 35(12):807-13. PubMed ID: 26446005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Study on determination of desloratadine in human serum and its pharmacokinetics by HPLC/MS].
    Lu XY; Sheng-Tu JZ; Chen ZG; Huang MZ; Zhou HL; Zheng GG
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2005 Jul; 34(4):372-4. PubMed ID: 16059990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of desloratadine poor metabolizer phenotype in healthy Jordanian males.
    Hakooz N; Salem II
    Biopharm Drug Dispos; 2012 Jan; 33(1):15-21. PubMed ID: 22271705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of effects of 5 and 10 mg oral desloratadine and levocetirizine on histamine-induced wheal and flare response in healthy volunteers.
    Bulca S; Bayramgürler D; Odyakmaz Demirsoy E; Yavuz M; Sikar Aktürk A; Bilen N; Kıran R
    J Dermatolog Treat; 2013 Dec; 24(6):473-6. PubMed ID: 23441762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of inhibition of cutaneous histamine reaction of ebastine fast-dissolving tablet (20 mg) versus desloratadine capsule (5 mg): a randomized, double-blind, double-dummy, placebo-controlled, three-period crossover study in healthy, nonatopic adults.
    Antonijoan R; García-Gea C; Puntes M; Pérez J; Esbrí R; Serra C; Fortea J; Barbanoj MJ
    Clin Ther; 2007 May; 29(5):814-822. PubMed ID: 17697901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and bioequivalence evaluation of omeprazole and sodium bicarbonate dry suspensions in healthy Chinese volunteers.
    Zhang R; Guo P; Zhou J; Li P; Wan J; Yang C; Zhou J; Liu Y; Shi S
    Sci Rep; 2023 Jan; 13(1):1113. PubMed ID: 36670124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics/pharmacodynamics of desloratadine and fluoxetine in healthy volunteers.
    Gupta S; Banfield C; Kantesaria B; Flannery B; Herron J
    J Clin Pharmacol; 2004 Nov; 44(11):1252-9. PubMed ID: 15496643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adult and paediatric poor metabolisers of desloratadine: an assessment of pharmacokinetics and safety.
    Prenner B; Kim K; Gupta S; Khalilieh S; Kantesaria B; Manitpisitkul P; Lorber R; Wang Z; Lutsky B
    Expert Opin Drug Saf; 2006 Mar; 5(2):211-23. PubMed ID: 16503743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and bioequivalence study of irbesartan tablets after a single oral dose of 300 mg in healthy Thai volunteers.
    Wittayalertpanya S; Chariyavilaskul P; Prompila N; Sayankuldilok N; Eiamart W
    Int J Clin Pharmacol Ther; 2014 May; 52(5):431-6. PubMed ID: 24725445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.